Marc Stapley

CEO Marc Stapley sells 138,051 VCYT shares at $50.12 via scheduled 10b5-1 plan; retains 440,494 shares post-sale

Marc Stapley, Chief Executive Officer of Veracyte, sold 138,051 shares (138.1K shares) for $6,919,585.49 on 2026-06-04 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-24, reducing his direct holdings from 578,545 to 440,494 shares. The sale represents a 23.9% reduction of pre-transaction holdings, executed at $50.12, near the 52-week high of $50.71, as the stock has gained 51.5% over the past 30 days and 47.5% over 90 days. The transaction is scheduled under a trading plan, so it reflects a pre-determined execution rather than a discretionary timing decision. Notably, Stapley's prior five sales at Veracyte have shown mixed results: three earlier 2025 sales posted negative 30-day and 90-day returns, while two March 2026 sales saw near-term declines (-9.3% and -11.1% at 30 days) followed by strong 90-day recoveries (+34.4% and +31.8%). The company's fundamentals remain solid with annual revenue growth of +16.0%, net income of $28,707,000.00, and a market cap of $3,984,844,791.18 ($4.0B), though the P/E of 45.40 reflects premium valuation. The CEO retains a substantial equity stake of 440,494 non-derivative shares post-transaction.

CEO Marc Stapley sold 45,523 shares for $1,637,594.15 across 2 transactions on 2026-03-04

Marc Stapley, CEO of Veracyte Inc., executed 2 separate sales totaling 45,523 shares for $1,637,594.15 on March 4, 2026, reducing his holdings by 11.3% to 357,554 shares. His cross-ticker track record shows a 100.00% well-timed rate across 10 prior sells with a 90-day average return of -20.6%, indicating a consistent pattern of selling before declines. At Veracyte specifically, all 3 prior sales occurred on the same date (2025-03-04) and were well-timed, with 90-day returns of -18.5%, -21.2%, and -22.2%, demonstrating the insider's historical ability to exit before deterioration. The current stock price of $33.85 is 31.4% below the 52-week high of $49.38, and down 24.1% over the past 90 days—aligning with the pattern that preceded this sale. The company shows strong fundamentals (revenue $131.9M, net income $19.1M, 16.0% annual growth) but trades at a P/E of 37.20, which may influence the timing of insider dispositions.

Director Marc Stapley sold 15,000 shares of GKOS on 2026-01-22 at blended avg $127.71, reducing stake by 28.6% to 37.4K shares

Marc Stapley, a director at Glaukos, executed 5 separate sales totaling 15,000 shares for $1,915,576.23 on 2026-01-22 at prices ranging from $126.07 to $129.78, trimming his holdings by 28.6% from 52.4K to 37.4K shares. The sales were executed at a blended average price of $127.71, well above the current market price of $124.27. While the stock has recovered +59.8% over the past 90 days and trades at a 30-day gain of +6.9%, his prior two sales at GKOS (both on 2023-12-14) were poorly timed against the 90-day window, with the stock rising +15.9% and +14.8% respectively after those transactions. His cross-ticker selling track record shows 5 prior sales with an average 90-day return of -6.2%, though this represents mixed timing. The company remains unprofitable on a full-year basis despite strong +21.8% annual revenue growth, which adds context to substantial insider liquidation activity.

VCYT CEO Stapley sold 52,697 shares for $1,756,855.23 across 3 transactions at $32.82–$34.37; stock down 29.5% from high

Marc Stapley, VERACYTE's Chief Executive Officer, executed 3 separate sales on 2025-03-04 totaling 52,697 shares (52.7K shares) for $1,756,855.23, reducing his holdings from 320,732 shares to 268,035 shares (-16.4% reduction). The CEO sold at prices ranging from $32.82 to $34.37 per share, with a blended average of $33.34, while the stock currently trades at $32.51—a 29.5% decline from its 52-week high of $46.14. Across Stapley's cross-ticker track record, his prior 2 open-market sells produced an average 90-day return of +15.3%, with a 0.00% well-timed rate (meaning those prior sells were followed by stock gains, indicating unfavorable timing). The company shows solid fundamentals—$115.9M in latest quarterly revenue, $15.2M net income, and 23.5% annual revenue growth—with a P/E of 28.27. The timing of this large CEO liquidation against the broader downward price trajectory (–25.7% over 30 days, –26.3% over 90 days) and the insider's historical pattern of poorly-timed sells merits investor scrutiny.